source
- Otsuka and Ionis report ALS drug ulefnersen meets primary endpoint in phase 3 trialOtsuka and Ionis have completed the Fusion phase 3 trial of ulefnersen, an RNA‑targeted therapy for ALS patients with mutations in the FUS gene. The study enrolled 89 participants, with 73 forming…
- Amgen's Dazodalibep Shows Positive Results in First Phase 3 Trial for Sjögren’s SyndromeAmgen announced that its experimental drug dazodalibep, acquired through the Horizon Therapeutics acquisition, met the primary endpoint in the first of two Phase 3 trials for Sjögren’s syndrome, a…